CD4 and obstructive sleep apnea syndrome: We divided unfavorable chemotherapy responses (PD) and favorable responses (PR+SD) as two cohorts, and found that the mRNA expression level of CD4/IFNGR2/CD68/CSF1R could predict favorable neoadjuvant chemotherapy responses in OSA target lesions (Figure 6B).